Targeted Diagnostics for Brain Health
Niki BioSolutions
Niki BioSolutions (Nasdaq: NIKI), formed in July 2026 through the merger of Aptorum Group Limited and DiamiR Biosciences Corp., is a clinical-stage life sciences company developing minimally invasive tests based on brain-enriched microRNAs in plasma, and delivering genomic and biomarker testing services through its CLIA-certified, CAP-accredited laboratory.
Our approach
Early detection and monitoring
of neurodegenerative and neurodevelopmental disorders, healthy aging
Targeted approach
brain-enriched microRNA biomarkers in plasma
Collaborations
with academia, medical centers, disease foundations and industry
Peer-reviewed publications
grant awards, patents
Our technology
Through DiamiR Biosciences, our wholly owned subsidiary, we combine more than a decade of microRNA biomarker research with an accredited clinical laboratory in New Haven, Connecticut.
Our work is focused on unmet needs in brain health and oncology, where earlier and less invasive detection can change how patients are identified, enrolled in clinical studies, and monitored over time.
Niki BioSolutions brings together five capabilities that are usually spread across several organizations.
Scientific expertise
Our team and advisors include the scientists who first described plasma microRNA biomarkers of mild cognitive impairment and who have published on microRNA biology in neurodegeneration and cancer.
Laboratory capabilities
Our New Haven laboratory is CLIA-certified, CAP-accredited, and holds a New York State clinical laboratory permit and licenses in additional states.
Product development
Assay development is led by scientists with experience developing molecular diagnostic tests, using RT-qPCR chemistries suited to a clinical laboratory setting.
Clinical validation
We conduct studies with Alzheimer's Disease Research Centers and academic medical centers, supported in part by National Institute on Aging funding.
Commercialization
We offer testing services to research and biopharmaceutical partners today, and we plan to launch our lead test as a laboratory-developed test.
Our mission
Our mission is to develop minimally invasive solutions for the early detection and monitoring of brain and synaptic health conditions, and to deliver high-quality genomic and biomarker testing that supports Pharma product development and the clinical needs of patients in Brain health, neurodegeneration, and other diseases.
We serve healthcare providers, research institutions, and life sciences organizations, and we collaborate with academic centers, disease foundations, and biopharmaceutical companies.